Navigation Links
Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
Date:8/30/2007

GRONINGEN, Netherlands, Aug. 31 /PRNewswire-FirstCall/ -- Oncology focused pharmaceutical development company Kiadis Pharma announced today that it has successfully completed a Phase II clinical trial evaluating its product Reviroc(TM). Reviroc is used to eliminate cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. Data from the clinical study revealed improved overall survival of Reviroc-treated patients. The successful completion of the clinical trial allows Kiadis Pharma to prepare for a Phase III clinical study.

Manja Bouman, CEO, Kiadis Pharma, comments: "We are obviously very pleased with the completion of this Phase II trial of Reviroc. It brings treatment with our product a step closer to patients with end stage blood cancer. Reviroc shares its development platform with two other Kiadis Pharma products: ATIR and Rhitol. The results of this trial therefore mark an important milestone in the development of our entire clinical product pipeline."

In the non-randomized open label study 25 patients, each of whom had reached end stage Non-Hodgkin's lymphoma, were treated in multiple centers in Canada. The objective of the study was to determine the safety of the Reviroc treatment and its ability to eliminate cancer cells from a contaminated graft. Reviroc-treated grafts all showed excellent engraftment, indicating that Reviroc does not negatively impact the graft itself.

The Reviroc clinical trial data was evaluated against a historical patient control group from the Center for International Blood and Marrow Transplant Research (CIBMTR). The results for Reviroc-treated patients were compared with results from the CIBMTR database for patients who had received an autologous transplant without Reviroc. The outcome of this comparison shows that the Reviroc-treated patient group had an 80% chance of survival at 3 years post transplantation, while the CIBMTR control group had a 55% chance of
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
(Date:1/15/2014)... Ill. , Jan. 15, 2014 The Cadence ... Medical Fitness Center by the Medical Fitness Association, a ... to achieve their full potential. The Cadence Fitness & ... the western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:4/23/2014)... 2014 The American Society for Radiation Oncology (ASTRO) ... Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO ... radiation therapy in the treatment of endometrial cancer. ... May-June 2014 issue of Practical Radiation Oncology ... ASTRO. The full-length guideline is available as an ...
(Date:4/23/2014)... BUFFALO, N.Y. A novel compound that targets an ... host of cocaine addiction behaviors, including relapse behavior, a ... research provides strong evidence that this may be a ... no effective medications exist., The UB research was published ... last week. , In the study, the compound, RO5263397, ...
(Date:4/23/2014)... that can rapidly screen a large cell population ... that population has been seriously lacking," said Virginia ... Royal Society of Chemistry journal Chemical Science ... coworkers have developed a novel technique that detects ... Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ). ...
(Date:4/23/2014)... a country as wealthy as the United States, it may ... not have access to adequate food due to lack of ... , Recent research at the University of Illinois using data ... that the seniors who are dealing with hunger are also ... 8.35 percent of Americans over age 60 faced the threat ...
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... older Americans offer only meager savings, particularly in urban ... charge seniors a modest fee, usually $12 to $25 ... minimal for many of the most popular name-brand drugs. ... -- Washington, Chicago and Seattle -- see savings of ...
... that one of the substance-propolis, a resinous product ... decay. Researchers at the University of Campinas, Brazil, ... Propolis is a potent inhibitor of glucosyltransferase (Gtf) ... promote the binding of cariogenic bacteria to teeth, ...
... decided to conduct tests for any Indian doctor having graduated ... ensure a higher standards amongst doctors, the government has made ... sources said today. , The ... specify that students who want to enrol in MBBS course ...
... estrogen, the new generations of birth control pills double the ... the newest pills are no safer than the older versions ... pills may be more dangerous than the second-generation ones. ... mix of high doses of estrogen and one of two ...
... drug treatment are not getting it. The survey on Drug ... problems with drugs and alcohol. Only about 122,000 of them ... are only the tip of the (drug abuse) iceberg," says ... non-profit drug-treatment program. The study shows that about 4.7 million ...
... for patent infringement by the US based AAI Pharma Inc for ... 180 days exclusivity to sell the drug's 40 mg dosage form ... and 20 mg dosage forms. DRL expects this to be a ... allows the patent holder to file a lawsuit to challenge the ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: